In immunocompetent mouse models, the combination not only delays tumor progression and improves survival beyond either monotherapy but also enhances lymphocytes infiltration and overcomes resistance associated with olaparib insensitivity and high WEE1 expression (Teo et al., 2023). Here, WEE1 is linked to neoplasm.